Company will showcase new assay at the
upcoming San Antonio Breast Cancer Symposium
MINNEAPOLIS, Dec. 10,
2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:
TECH) today announced that Asuragen, a Bio-Techne brand, launched a
highly sensitive ESR1 mutation monitoring assay. ESR1
gene mutations are known to be linked to hormone receptor-positive
(HR+) metastatic breast cancer. The research-use-only assay, which
consists of a qPCR detection kit as well as an isolation kit for
cell-free DNA and exosomal RNA, will be featured in the Asuragen
booth (#1429) at the San Antonio Breast Cancer Symposium beginning
on December 10th.
While mutations in the ESR1 gene are exceedingly rare in
cancer patients prior to treatment, the use of endocrine therapies
leads to the emergence of ESR1 mutations in as many as 40%
of patients with HR+ metastatic breast cancer. Identifying these
mutations as quickly as possible is crucial for clinicians to spot
the early warning signs of treatment resistance and adjust course
as appropriate. Unfortunately, most molecular testing technologies
lack the sensitivity needed to reliably and cost-effectively detect
these mutations.
Asuragen's new ESR1 mutation assay, which consists of the
QuantideX® qPCR ESR1 exoMutation Kit paired with
the ExoLution™ Plus cfDNA + exoRNA Isolation Kit, was designed to
detect 11 ESR1 ligand-binding domain mutations in samples at
very high sensitivity. It can be used with widely available qPCR
technology for easy implementation without the added cost of
adopting a new platform. By detecting the molecular signal from
both cell-free DNA and exosomal RNA, the assay achieves sensitivity
levels that were previously only attainable with much more
expensive, cumbersome, or lower plex technologies.
"With a growing number of candidate drugs
targeting ESR1 mutations in clinical trials, it is more
important than ever for laboratory scientists to be able to spot
the emergence of these mutations among individuals who have been
treated with aromatase inhibitors and other endocrine therapies,"
said Dr. Matt McManus, President of
Bio-Techne's Diagnostics and Spatial Biology Segment. "Pairing our
deep expertise in developing highly sensitive, qPCR-based assays
with our capabilities in extracting data from exosomes, puts
Bio-Techne in a unique position to provide a high-quality,
streamlined, and multiplexed ESR1 mutation assay for
broad use in clinical research laboratories."
For more product information, please visit
https://asuragen.com/portfolio/oncology/quantidex-esr1-exomutation-kit/.
Asuragen's ESR1 mutation assay is intended for research use
only and is not meant for use in diagnostic procedures.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences
company providing innovative tools and bioactive reagents for the
research and clinical diagnostic communities. Bio-Techne products
assist scientific investigations into biological processes and the
nature and progress of specific diseases. They aid in drug
discovery efforts and provide the means for accurate clinical tests
and diagnoses. With hundreds of thousands of products in its
portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has
approximately 3,100 employees worldwide. For more information on
Bio-Techne and its brands, please visit
http://www.bio-techne.com or follow the Company on social
media at Facebook, LinkedIn, Twitter or YouTube.
About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice
President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bio-techne-launches-esr1-mutation-monitoring-assay-302325875.html
SOURCE Bio-Techne Corporation
